The pharmacology of bosentan

Author： Breu V.   Ertel S.I.   Roux S.   Clozel M.  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.7, Iss.7, 1998-07, pp. : 1173-1192

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

By Jasper Dingemanse   Paul L.M. van Giersbergen  

Clinical Pharmacokinetics, Vol. 43, Iss. 15, 2004-01 ,pp. : 1089-1115

Adis International

Access to resources Recommend Favorite

Bosentan

By Prakash A.   Perry C.M.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 5, 2002-01 ,pp. : 335-343

Adis International

Access to resources Recommend Favorite

Bosentan

By Mathier Michael A   Ishizawar David  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 6, 2010-04 ,pp. : 1023-1034

Informa Healthcare

Access to resources Recommend Favorite

Bosentan: Hepatotoxicity: case report

By  

Reactions Weekly, Vol. 1, Iss. 1092, 2006-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Bosentan: A Viewpoint by Lewis J. Rubin

By Rubin L.J.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 5, 2002-01 ,pp. : 343-343

Adis International

Access to resources Recommend Favorite